BACKGROUND
Cancer survivors face an increased risk of second primary malignancies (SPMs). Understanding SPM incidence and risk factors is crucial for long-term survivorship care.
METHODS
This was a SEER-Medicare retrospective cohort study of breast, prostate, colon, or rectal cancer survivors diagnosed between 2003-2...
Tendai Kwaramba, Sarah J. Westvold, Jessica B. Long et al.· Journal of the National Canc...· 0 citations
40
Background:
The use of biologic therapy for patients with mCRC is incompletely characterized. We evaluated receipt of biomarker matched guideline concordant treatment with VEGF inhibitors (VEGFi), EGFR antibodies (EGFRa), and immune checkpoint inhibitors (ICI), assessing treatment by sociodemographic, clinic...
T. Salah, Jessica B. Long, John Rothen et al.· JCO Oncology Practice· 0 citations
Simple Summary Colorectal cancer frequently spreads to the liver, where tumors resist immunotherapy through poorly understood mechanisms. Using quantitative multiplexed immunofluorescence in two independent patient cohorts, we measured CD4+, CD8+, and FOXP3+ regulatory T-cells in matched primary tumors and liver metast...
Yasaman Rezaie, Kerryan Ashley, J. Zhang et al.· Cancers· 0 citations
These findings support comprehensive genomic profiling to identify ALK fusions in CRC, which may inform the use of ALK-directed therapies, and highlight the frequent co-occurrence of MSI-high disease within this subgroup.
Xuan-Yi Li, Faiza Yasin, D. Pavlick et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.